UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Regulator decides to delist Kolon TissueGene
by Jeong Sae-im
2019-08-27 12:15
Pharmaceutical sector’s job growth twice of all industries’ average
by Jeong Sae-im
2019-08-26 11:39
HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma
by Jeong Sae-im
2019-08-23 15:02
GenNBio to test transplanting pig’s pancreatic islet into human next year
by Jeong Sae-im
2019-08-23 13:53
Medical device makers to fight bias against homemade products
by Jeong Sae-im
2019-08-20 12:50
라인
Medipost’s stem cell therapy, cord blood bank show solid growth
by Jeong Sae-im
2019-08-16 16:18
Korean firms eyeing on growing orphan drug market
by Jeong Sae-im
2019-08-14 14:48
‘Koreans don’t recognize suicidal signals well’
by Jeong Sae-im
2019-08-13 11:14
‘CPhI Korea thriving on local firms’ zeal for drug export’
by Jeong Sae-im
2019-08-08 14:54
[Reporter’s Notebook] SillaJen should be ashamed of itself
by Jeong Sae-im
2019-08-07 13:59
라인
HLB to seek pre-NDA meeting with FDA for rivoceranib
by Jeong Sae-im
2019-08-06 15:43
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
by Jeong Sae-im
2019-08-05 14:49
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
by Jeong Sae-im
2019-08-05 11:26
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
by Jeong Sae-im
2019-08-02 15:45
Eutilex pipelines are underrated: CEO
by Jeong Sae-im
2019-08-01 16:08
라인
Biotech industry group urges Japan to withdraw export curbs
by Jeong Sae-im
2019-07-25 17:09
[Focus] Korean biopharmas eye US Humira market
by Jeong Sae-im
2019-07-25 15:02
Korean drugs strong in anti-reflux treatment market
by Jeong Sae-im
2019-07-22 15:15
MedPacto passes tech assessment, seeks KOSDAQ listing this year
by Jeong Sae-im
2019-07-19 17:01
Biopharmaceutical stocks face grim outlook in 2H
by Jeong Sae-im
2019-07-17 14:11
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top